Incyte's cash cow Jakafi chugs along with positive frontline results for GVHD

Five months after the FDA approved Incyte to expand its flagship Jakafi drug to patients with steroid-refractory acute graft-versus-host disease (GVHD), the company announced positive topline results from its Phase III study.